Presence Of Amphiregulin Autocrine-loop Predicts Sensitivity Of EGFR Wild Type Cancers To Gefitinib And Cetuximab
Researchers have discovered a biomarker in epidermal growth factor receptor (EGFR) wild-type non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) cell lines. This so-called amphiregulin autocrine loop appears to predict response to the targeted therapies gefitinib and cetuximab.
More: continued here
Filed under: Cancer on April 17th, 2008